Clinical Research/ Papers/ Abstracts
The studies presented on this page offer a comprehensive view of the effectiveness of Insulin Pump Therapy across various age groups in individuals with type 1 diabetes. These studies, conducted by esteemed researchers, provide critical insights into the benefits and outcomes of Continuous Subcutaneous Insulin Infusion (CSII) compared to conventional Multiple Daily Injections (MDI) therapy.
-
Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial
Navigating optimal glycemic control presents a formidable challenge for individuals grappling with type 1 diabetes. In our investigation, we delved into the efficacy of day-and-night hybrid closed-loop insulin delivery, juxtaposed with sensor-augmented pump therapy, among those aged 6 years and older contending with suboptimal diabetes management.
Read More -
Home Use of an Artificial Beta Cell in Type 1 Diabetes
The establishment of feasibility, safety, and effectiveness concerning the extended utilization of an artificial beta cell, also known as a closed-loop insulin-delivery system, within the comfort of one's home environment, remains an open question.
Read More -
Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes
For individuals managing type 1 diabetes outside of pregnancy, closed-loop (automated) insulin delivery stands out as a promising avenue for achieving superior glycemic control compared to sensor-augmented pump therapy. However, a notable gap exists in our understanding regarding the efficacy, safety, and practicality of implementing closed-loop therapy during pregnancy.
Read More -
Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Very Young Children: A Multicenter, 3-Week, Randomized Trial
Objective: Our aim was twofold: first, to evaluate the feasibility and safety of hybrid closed-loop insulin delivery in children aged 1-7 years with type 1 diabetes, and second, to assess the impact of diluted insulin on glucose control within this population.
Read More -
Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy
The objective of our study was to delve into the psychosocial experiences surrounding closed-loop technology among adults, children, and adolescents living with type 1 diabetes, as well as their parents. This exploration was conducted within the context of two multicenter, free-living, randomized crossover home studies.
Read More -
The artificial pancreas: What’s on the horizon? And will a fully closed-loop system ever be a reality?
As of July 2019, the closed-loop insulin delivery sector is experiencing rapid growth. Since the approval of Medtronic's MiniMed 670G by the US FDA in September 2016, no additional systems have been introduced to the market. However, a multitude of artificial pancreas systems, academic algorithms, and even open-source algorithms are in advanced phases of testing. It's anticipated that these innovations will make their way into the market in the coming years.
Read More